June 21, 2021
Learn More

July 18, 2022
Understanding Project Optimus
The FDA’s Oncology Center of Excellence has launched an initiative to reform the dose optimization and dose selection paradigm in oncology drug development. Known as Project Optimus, this initiative recommends a core change in how doses are selected during oncology clinical trials and post-approval studies.
Sirj Goswami, PhD, CEO, co-founder of InsightRX and Jason Rizzo, MBA, VP Global Biopharma Strategy discuss this topic in more detail in an article published by Applied Clinical Trials*.
Click here to read the full article. Read Full Article
Filter By:
Apply Filters
Category

January 03, 2023
Learn More
The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences

December 16, 2022
Learn More
What to Expect from AI-Enabled Drug Discovery in 2023

December 13, 2022
Learn More
InsightRX Provides Máxima Medical Center with Precision Dosing Guidance

December 01, 2022
Learn More
InsightRX to Showcase Precision Dosing Technology at ASHP 2022 Midyear Meeting

November 21, 2022
Learn More
Clinical Decision Support for Precision Dosing: Opportunities for Enhanced Equity and Inclusion in Health Care

October 19, 2022
Learn More
InsightRX to Showcase New Advances in Precision Dosing Technology during IDWeek 2022

October 11, 2022
Learn More
InsightRX Offers Precision Dosing Support for New Drug Categories

September 07, 2022
Learn More
The Evolution of Therapeutic Drug Monitoring for Tacrolimus

August 09, 2022
Learn More
Healix and InsightRX Provide Patient-Specific Precision Dosing for Outpatient Infusion Therapy

July 25, 2022
Learn More
InsightRX Precision Medicine Software Platform Selected by Amsterdam UMC 

July 18, 2022
Learn More
Understanding Project Optimus

June 01, 2022
Learn More